Back

Almost 1 in 2 patients with acute coronary syndrome are extremely high-risk and potential candidates for in-hospital triple lipid-lowering therapy: data from the CALLINICUS-Hellas Registry

27 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy of acute coronary syndromes in clinical practice Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Beta-blockers after STEMI: prognostic impact and predictors of adherence, results from the real-world FAST-STEMI registry
Doctor E. Ravetti (Orbassano, IT)
Abstract Slides Video
Presentation thumbnail
Changes of hospital-level variation in use of optimal medical treatment for long-term follow-up from a multi-level methodological approach
Doctor H. Kwak (Daegu, KR)
Abstract Slides
Presentation thumbnail
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
Professor R. Marcucci (Florence, IT)
Abstract Slides Video
Presentation thumbnail
One-month dual antiplatelet therapy following stent implantation in patients with acute coronary syndromes and high bleeding risk
Doctor C. Pivato (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Ticagrelor versus Clopidogrel in diabetes patients afflicted with acute coronary syndrome stratified by renal function
Doctor T. Wang (Taipei, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy of acute coronary syndromes in clinical practice

The Event

Event poster

ESC Congress 2023

27 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry
thumbnail
Congress Presentation
A significant gap remains in LDL-C targets despite the high prescription rate of oral intensive lipid-lowering therapy in post-ACS: there is a need for more widespread usage of PCSK9 inhibitors
thumbnail
Congress Presentation
Strategies to reach target lipid levels

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources